Pharmacologic induction of fetal hemoglobin production.

Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in adult patients with hemoglobin disorders. The understanding of the developmental regulation of γ-globin gene expression was followed by the identification of a number of chemical compounds that can reactivate HbF synthesis in vitro and in vivo in patients with hemoglobin disorders. These HbF inducers can be grouped in several classes based on their mechanisms of action. This article focuses on pharmacologic agents that were tested in humans and discusses current knowledge about the mechanisms by which they induce HbF.

[1]  R. Flavell,et al.  DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissues , 1980, Cell.

[2]  J. Hanover,et al.  The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. , 2005, Blood.

[3]  G. Henze,et al.  Oral isobutyramide reduces transfusion requirements in some patients with homozygous β-thalassemia , 2000 .

[4]  George J. Dover,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments] , 1992 .

[5]  T. Ley,et al.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.

[6]  A. Schechter,et al.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. , 2008, Blood.

[7]  Mark A. Hall,et al.  The Role of p22 NF-E4 in Human Globin Gene Switching* , 2004, Journal of Biological Chemistry.

[8]  P. Navas,et al.  Developmental Specificity of the Interaction between the Locus Control Region and Embryonic or Fetal Globin Genes in Transgenic Mice with an HS3 Core Deletion , 1998, Molecular and Cellular Biology.

[9]  G. Stamatoyannopoulos,et al.  Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. , 1999, Blood.

[10]  F. Grosveld,et al.  The active spatial organization of the beta-globin locus requires the transcription factor EKLF. , 2004, Genes & development.

[11]  B. Pace,et al.  Erk pathway inhibitor U0126 induces gamma-globin expression in erythroid cells. , 2005, Cellular and molecular biology.

[12]  D. Faller,et al.  Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. , 1998, Blood.

[13]  D. Lavelle,et al.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.

[14]  T. Townes,et al.  Differential Binding of Erythroid Krupple-like Factor to Embryonic/Fetal Globin Gene Promoters during Development* , 2006, Journal of Biological Chemistry.

[15]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[16]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[17]  R. Nagel,et al.  High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin , 1997, Molecular and cellular biology.

[18]  M. Gladwin,et al.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. , 2003, The Journal of clinical investigation.

[19]  J. Issa,et al.  Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation" , 2003, Science.

[20]  M. Cappellini,et al.  Expression of the γ‐globin gene is sustained by the cAMP‐dependent pathway in β‐thalassaemia , 2007 .

[21]  A. Schechter,et al.  Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. , 1996, Blood.

[22]  G. Kollias,et al.  Regulated expression of human A γ-, β-, and hybrid γβ-globin genes in transgenic mice: Manipulation of the developmental expression patterns , 1986, Cell.

[23]  R. Behringer,et al.  Human globin locus activation region (LAR): role in temporal control. , 1990, Trends in genetics : TIG.

[24]  JN Weiss,et al.  Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia , 1984 .

[25]  G. Stamatoyannopoulos,et al.  Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice , 1990, Nature.

[26]  A. Nienhuis,et al.  Treatment with Azacitidine of Patients with End-Stage β-Thalassemia , 1993 .

[27]  G. Serjeant.  Natural history and determinants of clinical severity of sickle cell disease , 1995, Current opinion in hematology.

[28]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[29]  S. Jane,et al.  Methylation-enhanced binding of Sp1 to the stage selector element of the human gamma-globin gene promoter may regulate development specificity of expression , 1993, Molecular and cellular biology.

[30]  A. Nienhuis,et al.  Inducibility of the HS II enhancer depends on binding of an erythroid specific nuclear protein. , 1990, Nucleic acids research.

[31]  M L Terrin,et al.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.

[32]  N. Olivieri,et al.  Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. , 1995, The New England journal of medicine.

[33]  S. Orkin,et al.  Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1. , 1990, Genes & development.

[34]  J. Morris,et al.  Fetal haemoglobin and early manifestations of homozygous sickle cell disease. , 1992, Archives of disease in childhood.

[35]  F. Costa,et al.  Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients , 2004, British journal of haematology.

[36]  G. Stamatoyannopoulos,et al.  On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. , 1989 .

[37]  O. Castro,et al.  Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea , 2002, British journal of haematology.

[38]  Richard D Moore,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. , 1992, Blood.

[39]  Tonya A Schneidereith,et al.  Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells. , 2006, Experimental hematology.

[40]  S. Brusilow,et al.  Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. , 1995, Blood.

[41]  G. Stamatoyannopoulos,et al.  FKLF-2: a novel Krüppel-like transcriptional factor that activates globin and other erythroid lineage genes. , 2000, Blood.

[42]  H. Cao.  Pharmacological Induction of Fetal Hemoglobin Synthesis using Histone Deacetylase Inhibitors , 2004, Hematology.

[43]  T. Ley,et al.  5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. , 1985, The Journal of clinical investigation.

[44]  M. Stevens,et al.  Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. , 1981, The Journal of pediatrics.

[45]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[46]  J. Strouboulis,et al.  Developmental regulation of a complete 70-kb human beta-globin locus in transgenic mice. , 1992, Genes & development.

[47]  G. Rodgers,et al.  Mortality in sickle cell disease. , 1994 .

[48]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[49]  A. Riggs,et al.  Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. , 1988, British Journal of Cancer.

[50]  W. C. Forrester,et al.  A deletion of the human beta-globin locus activation region causes a major alteration in chromatin structure and replication across the entire beta-globin locus. , 1990, Genes & development.

[51]  M. Groudine,et al.  β-globin Gene Switching and DNase I Sensitivity of the Endogenous β-globin Locus in Mice Do Not Require the Locus Control Region , 2000 .

[52]  M. Sutton,et al.  Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. , 2007, Blood.

[53]  H. Cario,et al.  Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis , 2002, Annals of Hematology.

[54]  S. J. Chen,et al.  Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Chunhui Hou,et al.  A positive role for NLI/Ldb1 in long-range beta-globin locus control region function. , 2007, Molecular cell.

[56]  J. Rochette,et al.  Fetal hemoglobin levels in adults. , 1994, Blood reviews.

[57]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Herman,et al.  Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. , 2003, Cancer research.

[59]  J. Schimenti,et al.  Fetal hemoglobin production in adult baboons by 5-azacytidine or by phenylhydrazine-induced hemolysis is associated with hypomethylation of globin gene DNA. , 1983, Progress in clinical and biological research.

[60]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[61]  M. Whitters,et al.  Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Stamatoyannopoulos.  Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.

[63]  F. Costa,et al.  Long‐term hydroxyurea therapy in beta‐thalassaemia patients , 2003, European journal of haematology.

[64]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[65]  C. Lowrey,et al.  In Vivo Formation of a Human β-Globin Locus Control Region Core Element Requires Binding Sites for Multiple Factors Including GATA-1, NF-E2, Erythroid Kruppel-like Factor, and Sp1* , 2001, The Journal of Biological Chemistry.

[66]  A. Carè,et al.  Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Cappellini,et al.  Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  G. Stamatoyannopoulos,et al.  Induction of human γ globin gene expression by histone deacetylase inhibitors , 2004 .

[69]  R. Nagel,et al.  Trial of recombinant human erythropoietin: three patients with thalassemia intermedia [letter] , 1992 .

[70]  R. Hoffman,et al.  2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.

[71]  G. Kollias,et al.  Position-independent, high-level expression of the human β-globin gene in transgenic mice , 1987, Cell.

[72]  D. Lavelle,et al.  Increased binding of SP1 to the γ‐globin gene promoter upon site‐specific cytosine methylation , 1994 .

[73]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[74]  G. Stamatoyannopoulos,et al.  F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study , 1993 .

[75]  J. Bieker,et al.  A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins , 1993, Molecular and cellular biology.

[76]  D. Faller,et al.  Delay in the fetal globin switch in infants of diabetic mothers. , 1985, The New England journal of medicine.

[77]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[78]  H. Pearson,et al.  Pharmacologic treatment of thalassemia intermedia with hydroxyurea. , 1994, The Journal of pediatrics.

[79]  W. C. Forrester,et al.  Evidence for a locus activation region: the formation of developmentally stable hypersensitive sites in globin-expressing hybrids. , 1987, Nucleic acids research.

[80]  B. Forget,et al.  δβ Thalassemia and Hereditary Persistence of Fetal Hemoglobin , 1991 .

[81]  M. Pembrey,et al.  Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. , 2020, Annals of internal medicine.

[82]  K. McIntyre,et al.  Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. , 1984, The New England journal of medicine.

[83]  G. Stamatoyannopoulos,et al.  Butyrate increases the efficiency of translation of γ-globin mRNA , 2005 .

[84]  O. Witt,et al.  Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. , 2003, Blood.

[85]  S. Jane,et al.  Induction of Human Fetal Globin Gene Expression by a Novel Erythroid Factor, NF-E4 , 2000, Molecular and Cellular Biology.

[86]  C. Lowrey,et al.  Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. , 2007, Journal of molecular biology.

[87]  G. Stamatoyannopoulos,et al.  Histone acetylation at the human β-globin locus changes with developmental age , 2004 .

[88]  C. Lowrey,et al.  Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. , 2007, Blood.

[89]  H. Bard,et al.  Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. , 1985, Pediatrics.

[90]  A. Schechter,et al.  5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia , 1983 .

[91]  R. Calzolari,et al.  Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia. , 1997, Hemoglobin.

[92]  O. Castro,et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.

[93]  G. Dover,et al.  Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. McDowell,et al.  Beta-globin locus control region HS2 and HS3 interact structurally and functionally. , 2003, Nucleic acids research.

[95]  A. Kulozik,et al.  SICKLE CELL DISEASE IN ORISSA STATE, INDIA , 1986, The Lancet.

[96]  D. Lavelle.  The molecular mechanism of fetal hemoglobin reactivation. , 2004, Seminars in hematology.

[97]  Jiahuai Han,et al.  p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors , 2003 .

[98]  R. Weinberg,et al.  Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.

[99]  D. Zwiers,et al.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[100]  R. Ware,et al.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. , 2004, Blood.

[101]  F. Grosveld,et al.  β-Globin Active Chromatin Hub Formation in Differentiating Erythroid Cells and in p45 NF-E2 Knock-out Mice* , 2007, Journal of Biological Chemistry.

[102]  Kirby D. Johnson,et al.  Chromatin domain activation via GATA-1 utilization of a small subset of dispersed GATA motifs within a broad chromosomal region. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[103]  F. Barton,et al.  Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. , 1995, Controlled clinical trials.